Quest Diagnostics Lifts Full-Year Outlook on Strong Q2 Beat
DGX sits 33% above its 52-week low of $165.777 on elevated volume (2.1× avg).
Summary
Quest Diagnostics posted Q2 2026 revenue of $3.04 billion (+10.2% YoY) and adjusted EPS of $3.12 (+19.1% YoY), and raised its full-year revenue and adjusted EPS guidance.
Key Events · Earnings and Guidance · DGX
-
Q2 Revenue and EPS Beat
Revenue grew 10.2% to $3.04 billion, with organic growth of 10.0%. Adjusted diluted EPS rose 19.1% to $3.12, driven by volume growth and operational leverage.
-
Full-Year Guidance Raised
Revenue guidance was raised to $11.95–$12.05 billion (from $11.78–$11.90 billion). Adjusted diluted EPS guidance moved up to $11.05–$11.25 (from $10.63–$10.83), above consensus.
-
Broad-Based Volume Growth
Requisition volume increased 13.1%, with organic volume up 13.0%, reflecting strong demand across physician, hospital, and consumer channels.
-
Advanced Diagnostics Momentum
Double-digit revenue growth was recorded in Alzheimer's blood tests, advanced cardiometabolic and endocrine tests, and liver fibrosis testing. The Haystack MRD test received New York State approval.
Analysis · DGX · Industrial Applications And Services
A robust second quarter saw revenue climb 10.2% to $3.04 billion and adjusted EPS reach $3.12, exceeding expectations. Management responded by raising full-year revenue and adjusted EPS guidance, with the new EPS range of $11.05–$11.25 now above consensus. Broad-based organic growth across physician, hospital, and consumer channels underpinned the performance, and the guidance increase signals confidence that demand for diagnostic services will remain strong.
At the time of this filing, DGX was trading at $221.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $23.2B. The 52-week trading range was $165.78 to $219.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.